Crossmark

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

Crossref DOI link: https://doi.org/10.1186/s40425-019-0568-2

Published Online: 2019-05-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aznar, M. Angela

Planelles, Lourdes

Perez-Olivares, Mercedes

Molina, Carmen

Garasa, Saray

Etxeberría, Iñaki

Perez, Guiomar

Rodriguez, Inmaculada

Bolaños, Elixabet

Lopez-Casas, Pedro

Rodriguez-Ruiz, Maria E.

Perez-Gracia, Jose L.

Marquez-Rodas, Ivan

Teijeira, Alvaro

Quintero, Marisol

Melero, Ignacio http://orcid.org/0000-0002-1360-348X
Funding

Funding for this research was provided by:

Ministerio de Economía, Industria y Competitividad, Gobierno de España (2017-83267-C2-1-R)

Fundación Científica Asociación Española Contra el Cáncer (NK grant)

Fundación BBVA (BBVA award)

Horizon 2020 Framework Programme (PROCROP)
License Information

Text and Data Mining valid from 2019-05-02
More Information

Article History

Received: 7 July 2018

Accepted: 15 March 2019

First Online: 2 May 2019

Ethics approval and consent to participate

: Not applicable

: Not applicable

: MQ, LP, PLC and MPO are full time employees in Bioncotech. IM reports receiving commercial research grants from BMS, Alligator and Roche and serves as a consultant/advisory board member for BMS, Merck-Serono, Roche-Genentech, Genmab, Incyte, Bioncotech, Tusk, Numab, Genmab, Molecular partners, F-STAR, Alligator, Bayer and AstraZeneca.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.